Karyopharm Therapeutics Inc. filings document the formal disclosures of a commercial-stage oncology company centered on XPOVIO (selinexor), clinical development programs, financing arrangements, and governance matters. Form 8-K reports include operating and financial results, preliminary revenue and liquidity disclosures, clinical and regulatory updates, material agreements, and capital-structure events.
The company’s SEC record also includes proxy materials for annual and special stockholder meetings, director elections, executive compensation, shareholder voting matters, and amendments to authorized share capacity. Additional filings describe private placements, common stock and warrant structures, sales under equity offering arrangements, and amendments to credit and guaranty agreements, including covenant and liquidity terms.
Karyopharm Therapeutics (KPTI) reported an insider equity award for its President and CEO, Richard Paulson, on 10/15/2025. He received 114,285 restricted stock units at $0 under the company’s 2022 Equity Incentive Plan. The RSUs convert into common stock on a one-for-one basis and vest 100% on December 31, 2026. Following the grant, Paulson’s beneficial ownership totaled 198,331 common shares, held directly. He is also listed as a director.
Karyopharm Therapeutics (KPTI) reported an officer equity grant. SVP, General Counsel & Secretary Michael Mano received 43,650 restricted stock units (RSUs) on 10/15/2025 at a price of $0. Each RSU converts into one share of common stock and vests 100% on December 31, 2026. Following the award, the reporting person beneficially owned 65,075 shares directly.
Karyopharm Therapeutics (KPTI) reported an executive equity award on a Form 4. EVP & Chief Commercial Officer Sohanya Cheng received 43,650 restricted stock units (RSUs) on 10/15/2025 at $0. The RSUs convert into common stock on a one-for-one basis and vest 100% on December 31, 2026. Following the award, Ms. Cheng beneficially owns 79,506 shares directly.
Karyopharm Therapeutics (KPTI) reported an insider equity grant: EVP, CFO & Treasurer Lori Macomber received 43,650 restricted stock units (RSUs) on 10/15/2025 at a price of $0. The RSUs convert into common stock on a one-for-one basis and vest 100% on December 31, 2026. Following the award, her beneficial ownership stands at 54,316 shares. The reported share amounts reflect the company’s one‑for‑fifteen reverse stock split effected on February 25, 2025.
Karyopharm Therapeutics (KPTI) completed a set of financing transactions. The company issued 9.00% senior secured convertible notes in two series: $15.0 million aggregate principal amount due 2028 and $103.5 million aggregate principal amount due 2029. It also borrowed $12.5 million under its existing credit and guaranty agreement.
The company entered into indentures for each note series with Wilmington Savings Fund Society as trustee and collateral agent and executed related registration rights agreements with term loan lenders. Exhibits include a first amendment and waiver to the credit agreement, a note purchase agreement, exchange agreements, warrant forms, a pre-funded warrant form, and a sixth amendment to the revenue interest financing agreement.
Shares outstanding were 15,926,939 as of October 14, 2025, assuming no exercise of pre-funded warrants or warrants and no conversions of the new convertible notes.
Karyopharm Therapeutics, Inc. disclosed an amendment and related licensing activity centered on its oncology drug selinexor. Under an Amendment No. 4 dated August 7, 2025, Karyopharm granted Berlin-Chemie AG (an affiliate of the Menarini Group) a non-exclusive license to develop and an exclusive license to commercialize selinexor for human oncology indications across Europe (including the United Kingdom), Latin America, certain Middle East and Africa regions and other specified countries. The filing also references exchange transactions involving pre-funded warrants and warrants to purchase common stock (including warrants for an aggregate of 2,502,151 shares and pre-funded warrants for 552,164 and 1,404,087 shares) and notes a correction to a prior 10-Q paragraph. The notice was accompanied by a press release dated October 8, 2025.
Karyopharm Therapeutics (KPTI) reported an insider transaction by its Chief Accounting Officer, Kristin Abate. On 10/01/2025, Abate sold 362 shares of common stock at a weighted average price of $6.296. Following the sale, she beneficially owned 10,046 shares directly.
According to the filing, the broker-assisted sale was executed under a durable automatic sale instruction plan adopted on May 27, 2021, to satisfy withholding taxes upon the vesting of PSUs, and does not represent a discretionary trade.
Richard A. Paulson, President, CEO and a director of Karyopharm Therapeutics (KPTI), reported the vesting of 2,800 performance-based restricted stock units (PSUs) on September 12, 2025. These PSUs were granted in February 2023 and were earned after the Compensation Committee certified completion of enrollment in the company’s Phase 3 SENTRY trial; each earned PSU represents the contingent right to one share and vested upon certification. Following vesting, a broker-assisted sale executed under an automatic sale instruction plan sold 1,257 shares on September 15, 2025 at $6.43 per share to satisfy withholding tax obligations. After these transactions, the reporting person beneficially owned 84,046 shares.
Michael Mano, SVP, General Counsel & Secretary of Karyopharm Therapeutics (KPTI), reported that 612 performance-based restricted stock units (PSUs) were certified as earned and vested following achievement of a clinical enrollment milestone for the company’s Phase 3 SENTRY trial, converting into the contingent right to the same number of common shares. To satisfy tax withholding on the vested PSUs, the reporting person executed a broker-assisted sale of 234 shares at an average price of $6.43, leaving beneficial ownership of 21,425 shares.
Stuart Poulton, EVP and Chief Development Officer of Karyopharm Therapeutics (KPTI), reported the vesting of 888 performance-based restricted stock units (PSUs) on 09/12/2025 after the company certified completion of enrollment in its Phase 3 SENTRY trial. Each PSU converts to one share, increasing his beneficial ownership to 28,111 shares. On 09/15/2025 he executed an automatic, broker-assisted sale of 401 shares at $6.43 to cover withholding taxes, leaving 27,710 shares beneficially owned. The PSUs were originally granted in February 2023 and vested upon certification by the Compensation Committee. The Form 4 was signed by an attorney-in-fact on 09/16/2025.